$1.180
+0.010 (+0.85%)At close
RGNT Comparative Benchmarking
In the context of the broader market, RGNT competes directly with industry leaders such as BON and CALC. With a market capitalization of $8.28M, it holds a significant position in the sector. When comparing efficiency, RGNT's gross margin of N/A stands against BON's 27.01% and CALC's N/A. Such benchmarking helps identify whether Regentis Biomaterials Ltd is trading at a premium or discount relative to its financial performance.
Regentis Biomaterials Ltd Financial Performance
The company has shown significant volatility with a 5-day change of -13.87% and a 20-day change of -26.25%. Its current ratio is very low at 0.08, indicating liquidity issues, and it has a total equity of only 7,681,000 USD as of Q2 2026, which is a recovery from previous losses.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.